| 17.08 0.9 (5.56%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 22.71  |
1-year : | 26.53 |
| Resists | First : | 19.45 |
Second : | 22.71 |
| Pivot price | 16 |
|||
| Supports | First : | 15.74 |
Second : | 13.44 |
| MAs | MA(5) : | 16.81 |
MA(20) : | 16.49 |
| MA(100) : | 21.97 |
MA(250) : | 30.54 |
|
| MACD | MACD : | -0.7 |
Signal : | -1 |
| %K %D | K(14,3) : | 75.2 |
D(3) : | 70.8 |
| RSI | RSI(14): 49.5 |
|||
| 52-week | High : | 44.41 | Low : | 13.44 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ IDYA ] has closed below upper band by 19.8%. Bollinger Bands are 13.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 17.13 - 17.22 | 17.22 - 17.3 |
| Low: | 15.98 - 16.06 | 16.06 - 16.15 |
| Close: | 16.94 - 17.08 | 17.08 - 17.22 |
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Wed, 16 Apr 2025
Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later - Seeking Alpha
Mon, 14 Apr 2025
Major FDA Breakthrough: IDEAYA's Eye-Saving Cancer Drug Advances to Phase 3 Trial - Stock Titan
Thu, 10 Apr 2025
IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer - PR Newswire
Tue, 01 Apr 2025
IDEAYA Leadership to Showcase Ophthalmology and Oncology Progress at Two Elite Conferences - Stock Titan
Mon, 31 Mar 2025
IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 88 (M) |
| Held by Insiders | 8.663e+007 (%) |
| Held by Institutions | 1 (%) |
| Shares Short | 8,900 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.2459e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 59.1 % |
| Return on Equity (ttm) | -23.1 % |
| Qtrly Rev. Growth | 7e+006 % |
| Gross Profit (p.s.) | 153.92 |
| Sales Per Share | -64.06 |
| EBITDA (p.s.) | -5.64059e+008 |
| Qtrly Earnings Growth | -3.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -248 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.27 |
| Price to Cash Flow | 0.71 |
| Dividend | 0 |
| Forward Dividend | 9.88e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|